Exactly when The Medicine Co.'s top seller will see competition isn't clear – highlighting industry concerns with FDA review times for ANDAs. Hospira and Sagent have tentative approval and several other firms have pending applications.
The Medicines Co. could face generic competition for its anticoagulant Angiomax (bivalirudin) four years earlier than expected now that the U.S. Court of Appeals for the Federal Circuit has ruled two patents covering the drug are invalid.
Last year, a district court found that Hospira Inc. failed to prove that claims in the patents were invalid...
US FDA critics have long decried the practice of using informal communications to convey regulatory expectations as podium policy. In the Makary era, the phrase may need to be updated because the agency now seems to be specializing in policy by podcast.
Tala Fakhouri said the agency’s use of the AI tool in the review process has generated lots of questions.
Kumar takes over as acting director of the Center for Biologics Evaluation and Research’s Office of Therapeutic Products days after director Nicole Verdun was ousted.
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
The former CDER director said she tells sponsors not to conduct an FDA-recommended study design or randomized trial if it will not work.
Artificial intelligence tools used for clinical research should be developed with input from patients and focus on their needs and abilities, FDA experts said.
